MKI67 and neoplasm: Different molecular markers including sex hormone receptors (ER, PR), receptor of epidermal growth factors (HER2), markers of active proliferation (Ki-67, survivin, NGAL), and metastatic potency (MMP9, SK1, DcR3, CIX2, EZH2) are used currently in clinical practice to evaluate tumor properties and define the optimal therapeutic approaches.